Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Proscia logo — Proscia is fighting cancer by changing the way the world pra...

Proscia

Proscia is fighting cancer by changing the way the world practices pathology. Join us.

Founded 2014 United States Philadelphia, United States 101 employees Series C Total: $130.52M AI, Biotechnology +1

General Information

Company Name Proscia
Founded Year 2014
Location United States Philadelphia, United States
Employees 101
Industries AI, Biotechnology, Life Sciences
Funding Stage Series C
Social

BounceWatch is an independent company data service, not affiliated with Proscia. To contact Proscia, visit proscia.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Proscia

Proscia is a leading player in the fight against cancer, revolutionizing the field of pathology with intelligent software. Established in 2014, the company operates in the AI, Biotechnology, and Life Sciences sectors and is based in the United States.

The $9.00M Series C investment secured by Proscia on 11 January 2024 has garnered notable support from a consortium of investors including Flybridge, Fusion Fund, Scale Venture Partners, Triangle Peak Partners, Robin Hood Ventures, Emerald Development Managers, Highline Capital, Hitachi Ventures, Robo Global Ventures, and Razor's Edge Ventures.

Proscia's commitment to changing the landscape of pathology and its collaborative approach have captured the attention and support of leading investors, positioning the company as a significant player in the advancement of cancer treatment and diagnostic processes.

Taxonomy: Proscia, digital pathology, pathology operations, cancer diagnosis, patient outcomes, intelligent software, computing technologies, cloud computing, medical imaging, cancer research, medical software

Funding Rounds & Investors (8)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $50.00M 9
Fusion Fund Insight Partners Triangle Peak Partners
Fusion Fund, Insight Partners +7
20 Mar 2025
Series C $9.00M 10
Flybridge Fusion Fund Scale Venture Partners
Flybridge, Fusion Fund +8
11 Jan 2024
Series C $36.62M 9
Alpha Intelligence Capital Scale Venture Partners Triangle Peak Partners
Alpha Intelligence Capital, Scale Venture Partners +7
03 Jun 2022
Series B $23.00M 2
Scale Venture Partners Hitachi Ventures
Scale Venture Partners, Hitachi Ventures
30 Nov 2020
Series B $673.00K 1
Robin Hood Ventures
Robin Hood Ventures
23 Nov 2020
Series A $8.30M 6
Flybridge Fusion Fund SoGal Ventures
Flybridge, Fusion Fund +4
26 Sep 2018
Seed Round $927.20K -
10 May 2017
Seed Round $2.00M 4
A-Level Capital Robin Hood Ventures Emerald Development Managers
A-Level Capital, Robin Hood Ventures +2
05 Jul 2016

Latest News

View All
Sağlık girişimi Proscia, 50 milyon dolar yatırım aldı — Webrazzi
Sağlık girişimi Proscia, 50 milyon dolar yatırım aldı
Webrazzi Mar 20, 2025

Proscia Alternatives & Competitors

View All Alternatives
Proscia vs
Neurabot Lab
Neurabot Lab Indonesia

Neurabot Lab is digital laboratory 4.0 platform and fighting cancer by AI technology in computationa...

Grant
10 employees
AI, Analytics
Compare Proscia vs Neurabot Lab
Proscia vs
Deep Bio Inc.
Deep Bio Inc. Korea South

Al healthcare company with in-house expertise in deep learning and cancer pathology.

Series B
30 employees
AI, Biotechnology
Proscia vs
MobileODT
MobileODT Israel

A FemTech company. Creating a new paradigm in cervical cancer screening and treatment.

Series C
13 employees
AI, Biotechnology
View all alternatives

FAQ About Proscia

Proscia is fighting cancer by changing the way the world practices pathology. Join us.
Proscia was founded in 2014.
Proscia is headquartered in Philadelphia, United States.
Proscia operates in AI, Biotechnology and Life Sciences. Its work centres on Proscia, digital pathology, pathology operations and cancer diagnosis.
Proscia has approximately 101 employees.
Proscia has completed 8 funding rounds, raising a total of $130.52M. The latest funding stage is Series C.
Top alternatives and competitors to Proscia include Neurabot Lab, Deep Bio Inc., MobileODT, Deep Lens (acquired by Paradigm), VitaDX. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Proscia and Neurabot Lab are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Proscia, https://bouncewatch.com/company/proscia, updated 25 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes